Janssen’s Tremfya Approved in Canada for Active Psoriatic Arthritis

September 11, 2020

Health Canada has approved Janssen’s Tremfya (guselkumab injection) for adults with active psoriatic arthritis.

The approval was based on results from two phase 3 trials in which Tremfaya significantly improved symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis compared to a placebo. The drug can be used alone or with a conventional disease-modifying, anti-rheumatic drug, such as methotrexate.

Tremfaya is also approved in the U.S., Japan and Brazil for the treatment of active psoriatic arthritis.

View today's stories